type 2 diabetes
Conditions
Interventions
the type 2 diabetes group:current anti-diabetic treatments
the normal glucose tolerance group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Normal glucose tolerance group: 1) subjects aged 18-75 years; 2) subjects with normal results of blood tests, such as complete blood count and blood chemistries, as well as urinalysis; 3) BMI from 18.5 to 24.9 kg/m2; 4) subjects with normal blood lipid, blood pressure as well as blood glucose and insulin in OGTT; 5) subjects not been prescribed with any drug which might influence the metabolism of blood glucose within 1 month before screening; 6) subjects who have signed the information consent form. Type 2 diabetes group: 1) subjects aged 18-75 years; 2) subjects with diabetes according to WHO1999: either fasting plasma glucose (FPG) >=7.0 mmol/L or 2h postprandial plasma glucose (2h PG) >=11.1 mmol/L in OGTT; 3) subjects with diabetes duration of more than 6 months; 4) subjects only treated with oral anti-diabetic drugs and the anti-diabetic approach remaining unchanged within 3 months before screening; 5) subjects not been prescribed with any drugs which might influence the metabolism of blood glucose within 1 month before screening; 6) subjects who have signed the information consent form.
Exclusion criteria
Exclusion criteria: 1) subjects treated with anti-postprandial hyperglycemic drugs, such as alpha-glucosidase inhibitors, glinides, DPP4 inhibitors, GLP-1 analogues and insulin, within 3 months before screening; 2) patients with unstable angina pectoris, severe angina pectoris, myocardial infarction or congestive heart failure; 3) patients with severe hepatic or renal dysfunction (AST and ALT > 2 folds of the upper limits of normal range respectively; Creatinine > 1.2 folds of the upper limit of normal range or eGFR <30ml/min); 4) subjects with any potential factors which might result in sharp fluctuations of blood glucose, such as acute infection, injury, surgical operation and malignant tumour; 5) pregnant and lactation women; 6) patients with any fatal diseases; 7) subjects with psychological diseases or poor self-cognition; 8) subjects who have taken part in other clinical trials within 3 months before screening; 9) Other conditions assessed by the investigators not appropriate for participating in this trail.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Curve (AUC)-basal blood glucose (BBG), AUC-postprandial blood glucose (PBG), AUC-total blood glucose all day (T) in CGMS;HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| asting and postprandial blood glucose in OGTT; | — |
Countries
China
Contacts
Public ContactXingu Ran
Outcome results
None listed